Evidence map›Paper›PMID 29161364›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.

N I Cherny, U Dafni, J Bogaerts, N J Latino, G Pentheroudakis, J-Y Douillard, J Tabernero, C Zielinski, M J Piccart, E G E de Vries

Abstract readCommentLetter
PubMed Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

N I ChernyCancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: mcbs@esmo.org.
U DafniLaboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
J BogaertsMethodology Direction, EORTC Headquarters, Brussels, Belgium.
N J LatinoESMO Head Office, Lugano, Switzerland.
G PentheroudakisMedical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
J-Y DouillardESMO Head Office, Lugano, Switzerland.
J TaberneroMedical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
C ZielinskiDivision of Oncology, Medical University Vienna, Vienna, Austria.
M J PiccartJules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium.
E G E de VriesDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Medical OncologyNeoplasmsHumans

Identifiers

PMID29161364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.